Vanda Pharmaceuticals Balances Growth With Rising Risks
Vanda Pharmaceuticals ((VNDA)) has held its Q4 earnings call. Read on for the main highlights of the call.
Valentine's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Vanda Pharmaceuticals’ latest earnings call painted a cautiously balanced picture for investors. Management highlighted strong prescription momentum for Fanapt, rising group revenues and multiple late‑stage pipeline wins, but these positives were offset by a large reported net loss, sharply higher operating costs, cash burn concerns and mounting pressure on legacy product HETLIOZ.
Fanapt Strong Commercial Growth
Fanapt remained the star of Vanda’s portfolio with full‑year net product sales climbing 24% to $117.3M as prescriptions surged. Total prescriptions rose 28% and new‑to‑brand scripts jumped 149%, while Q4 sales grew 25% year over year to $33.2M with TRx up 36% and NBRx more than doubling.
Company Revenue Growth
Overall revenue trends stayed positive even as product dynamics shifted. Total revenues for 2025 increased 9% to $216.1M, with fourth‑quarter revenue up 8% year over year and 2% sequentially to $57.2M, underscoring the growing contribution from Fanapt as HETLIOZ slid.
Regulatory Approval for Nereus
A major regulatory win came with the FDA approval of tradipitant, branded Nereus, for prevention of motion‑induced vomiting. Management called it the first new oral pharmacologic option in over four decades for this indication, with commercial launch targeted for late Q2 or early Q3 2026.
Robust Late-Stage Pipeline and Submissions
Beyond Nereus, Vanda emphasized a crowded late‑stage pipeline aimed at diversifying future revenue. Key milestones include a BLA for imsidolimab in generalized pustular psoriasis, an NDA under review for bipolar I disorder and schizophrenia, and several Phase III programs in depression, long‑acting iloperidone, social anxiety and PONVORY expansion.
Guidance and Growth Outlook
Management set 2026 revenue guidance for current products at $230M–$260M, implying about 13% growth at the midpoint. Fanapt is expected to lead with $150M–$170M of sales and roughly 36% year‑on‑year growth, driven mainly by continued prescription volume gains rather than price.
Commercial Capability Expansion
To sustain Fanapt momentum and prepare for future launches, Vanda has rapidly scaled its commercial footprint. The sales force nearly doubled to roughly 300 representatives by year‑end 2025, supplemented by around 50 specialty reps and supported by a direct‑to‑consumer campaign launched earlier in the year.
PONVORY Sequential Improvement
PONVORY remained a smaller but stabilizing contributor as full‑year sales slipped 2% to $27.4M. However, Q4 trends improved with revenue rising to $7.6M, up 17% versus the prior year and 8% sequentially, as underlying patient demand grew modestly over the last three quarters.
Large Net Loss from One-Time Tax Charge
Headline profitability deteriorated sharply, reflecting both underlying spending and a one‑off tax adjustment. The company reported a 2025 net loss of $220.5M versus $18.9M a year earlier, including a noncash $113.7M income tax expense tied to a valuation allowance on deferred tax assets.
Significant Operating Expense Increase
Operating expenses rose steeply as Vanda invested in launches and pipeline progress. Full‑year operating costs jumped to $367.3M from $239.4M, driven by higher SG&A and R&D, while Q4 expenses climbed to $97.6M, up more than $34M year over year and weighing on margins.
Cash Position and Expected Higher Cash Burn
The heavier spend is already pressuring the balance sheet, with cash, equivalents and securities falling to $263.8M at year‑end. Management cautioned that cash burn in 2026 will likely exceed 2025 levels and declined to provide explicit cash guidance, signaling ongoing funding and execution risk.
HETLIOZ Sales Decline and Generic Pressure
Legacy sleep‑disorder drug HETLIOZ continued to face intense generic competition and pricing pressure. Net sales fell 7% to $71.4M for the year and dropped 18% in Q4 to $16.4M, with management warning that elevated channel inventory and generics could drive further declines.
Unfavorable Gross-to-Net Dynamics
Despite strong prescription growth, Fanapt’s revenue conversion was hampered by adverse gross‑to‑net factors. Management cited Medicare redesign, expanded co‑pay support and a heavy Medicaid mix, noting that Medicaid, at roughly 30%–40% of volume, can even generate negative revenue contribution.
Clinical Enrollment Delays and Execution Risks
Execution risk also surfaced in the clinic as some trials progressed slower than planned. The Phase III program for iloperidone LAI is behind schedule due to European launch dynamics and reluctance around placebo control, while enrollment timelines for certain Phase III studies, including GLP‑1‑related work, remain uncertain projections.
Inventory and Quarterization Risks
Short‑term revenue visibility is further clouded by inventory and timing issues across channels. Fanapt wholesaler inventory sits slightly above the historical range and HETLIOZ specialty‑pharmacy stock is elevated, with management flagging potential Q1 disruption from insurance transitions and quarterization effects on reported sales and cash.
Forward-Looking Guidance and Outlook
For 2026, Vanda’s outlook centers on continued Fanapt growth and slow PONVORY improvement while excluding potential upside from new launches like Nereus or pending approvals. Guidance calls for $230M–$260M in revenue, with other products expected at $80M–$90M and management warning that higher cash burn, inventory overhang and insurance resets could make quarterly results choppy.
Vanda’s earnings call ultimately framed a classic high‑risk, high‑reward setup for investors. Strong Fanapt growth, a newly approved Nereus franchise and a broad late‑stage pipeline offer clear upside, but the combination of rising cash burn, deepening losses, HETLIOZ erosion and operational risks means execution over the next year will be critical to sustaining the growth story.
